Immuron Limited
IMRNHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the healthcare sector, Immuron Limited (IMRN) is listed under Biotechnology. The company carries a $14.9M market cap, placing it firmly in the micro-cap category. It operates through two segments, Research and Development; and Hyper-immune Products.
Market Cap
$14.9M
Beta
0.52
P/E (TTM)
—
P/E (Fwd)
-184.00
EPS (TTM)
$-0.37
EPS (Fwd)
$-0.01
ROE
-40.3%
ROA
-21.7%
Cash
$9.0M
Total Debt
$189,543
Free CF
-$2.3M
52W Change
-6.3%
Annual Financials
Cash vs Debt
Where IMRN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, IMRN finished 19.39% above its 150-day moving average ($0.98) and 13.59% above its 200-day moving average ($1.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IMRN overbought or oversold?
At the September 3, 2026 close, IMRN's RSI(14) was 54.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Immuron Limited holds $9.0M in cash against $190K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$2.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -40.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $765K (2022) to $7.3M (2025), reflecting a 852% increase over the period.
The relatively low beta of 0.52 suggests IMRN is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, IMRN has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Immuron Limited's trajectory.